A combination of Novartis' Afinitor and Pfizer's Aromasin failed to reach
statistical significance in a trial’s secondary endpoint of overall
survival.Eagerly-awaited results from the BOLERO-2 trial looking at the mTOR inhibitor Afinitor (everolimus) plus the aromatase inhibitor Aromasin (exemestane) were presented at the European Breast Cancer Conference in Glasgow and proved disappointing. In the study of women with advanced oestrogen receptor-positive breast cancer, median survival was 31 months for the combo versus 26.6 months for those on Aromasin monotherapy.
Previously reported results had shown the primary endpoint of progression-free survival to be clinically meaningful and statistically significant. Slightly fewer patients (10%) in the everolimus arm had received salvage chemotherapy after cancer progression and no new safety concerns were identified.
Presenting the results, Martine Piccart of the Jules Bordet Institute in Brussels said she hoped ongoing studies would identify breast cancer patients most likely to benefit from mTOR inhibition. However, “so far we have not been very successful,” she added.
Read more at: http://www.pharmatimes.com/Article/14-03-25/Afinitor_Aromasin_combo_disappoints_in_breast_cancer_trial.aspx#ixzz2x2osg4xV
No comments:
Post a Comment